Major histocompatibility complex class II presenting HIV-1 envelope glycoprotein peptides (MHC II-HIV-1 Env pMHC)

The Major Histocompatibility Complex Class II (MHC II) molecules presenting HIV-1 Envelope (Env)-derived peptides represent a critical immunological complex for the recognition of HIV-infected cells by the adaptive immune system. MHC II molecules, primarily expressed on professional antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells, present exogenous or endogenous viral antigens (gp120 and gp41) to CD4+ T helper cells. This interaction is essential for orchestrating both cellular and humoral immune responses, including the maturation of B cells into antibody-secreting plasma cells. In the context of HIV-1 infection, the virus employs several strategies to subvert this pathway, most notably through the Nef protein, which downregulates surface MHC II expression to evade immune detection. Therapeutically, these pMHC complexes are targeted by novel vaccine strategies designed to elicit potent T cell help and by TCR-mimic (TCRm) antibodies or bispecific molecules that redirect T cells to kill infected reservoirs. However, the interaction between MHC II and the CD4 binding site on HIV-1 Env also poses challenges for CD4-based biologics, which may suffer from off-target binding to MHC II, leading to poor pharmacokinetics and rapid systemic clearance.

Other names

MHC II-HIV-1 Env complexHLA-DR presenting HIV-1 Env peptidesHIV-1 Env peptide-MHC II complexgp120-MHC II complexgp41-MHC II complexpMHC II (HIV-1 Env)

Presentation of HIV-1 envelope-derived epitopes to CD4+ T helper cells to initiate adaptive immune responses; target for TCR-mimic antibodies and bispecific molecules to redirect T cell-mediated killing of infected cells.